DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06354101

Withdrawn

The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

The VITALITY Registry

Lead sponsor

CorEvitas

Assets

Semaglutide / Tirzepatide

Listed sites

0

Recruiting sites

—

Enrollment

—

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Main Objective of Registry

Identifiers

Registered as

NCT IDNCT06354101
Org study IDCorEvitas-VITALITY

Timeline

Milestones

Study start2023-07-01actual
Primary completion2023-07-01actual
Study completion2023-07-01actual
Study first posted2024-04-09actual
Last update posted2024-04-09actual

Assets

Investigational agents

SemaglutideTirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

This is a prospective, observational registry to study metabolic health in individuals.

Inclusion criteria

•At least 18 years of age (or age of majority)
•Willing to provide consent to participate

Exclusion criteria

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Main Objective of Registry

Time frame:Up to 10 years

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.